AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.111

Page 2

Serial Number: 09/512,926

Filing Date: February 25, 2000

Title: METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELIALLY-COMPROMISED VASCULAR SMOOTH MUSCLE

## In the Claims

Please amend the claims as follows. This set of claims is intended to reflect amendments to claims 1 and 7-10.

ento

1. [Currently Amended] A method to normalize the contractile response of an endothelially-compromised vascular smooth muscle cell to a vasoconstrictor agonist in a patient in need of such normalization, comprising administering a pharmaceutically effective amount of a CLC3 blocker, or a pharmaceutically acceptable salt thereof.

## 2-5. [Previously Canceled]

- 6. [Previously Amended] A method of claim 23, wherein the wherein the compound administered is 1-p-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, or a pharmaceutically acceptable salt thereof.
- 7. [Currently Amended] A method of claim 23, wherein said endothelium damage is the result of the patient has diabetes.
- 8. [Currently Amended] A method of claim 23, wherein said endothelium damage is the result of patient has had a surgical procedure.
- 9. [Currently Amended] A method of claim 23, wherein said endothelium damage is the result or cause of the patient has hypertension.
- 10. [Currently Amended] A method of claim 23, wherein said endothelium damage is the result or cause of the patient has coronary artery disease.
- 11. [Previously Amended] A method of claim 23, which further comprises administering a pharmaceutically-effective compound selected from the group consisting of: an anti-diabetes



AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.111

Page 3 Dkt: 875.039US1

Serial Number: 09/512,926

Filing Date: February 25, 2000

METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELIALLY-COMPROMISED VASCULAR SMOOTH MUSCLE

agent; an anti-hypertension agent; an anti-coronary artery disease agent; and an anti-restenosis agent.

- 12-13. [Previously Canceled]
- 14-21. [Previously Withdrawn]
- 22. [Previously Canceled]
- [Previously Amended] A method of claim 1, wherein the CLC3 blocker is a compound of 23. Formula I



$$R^4R^5N(CH_2)_nO$$

wherein

either R4 is H or a lower alkyl radical and R5 is a lower alkyl radical, or R4 and R5 are joined together with the adjacent nitrogen atom to form a heterocyclic radical;

R<sup>6</sup> is H or a lower alkyl radical;

R<sup>7</sup> is H, halo, OH, a lower alkyl radical, or is a buta-1,3-dienyl radical which together with the adjacent benzene ring forms a naphthyl radical;

R<sup>8</sup> is H or OH; and

n is 2;

or a pharmaceutically acceptable salt thereof.

24. [Previously Canceled]